Psychedelic drugs have been used as treatments in indigenous cultures for thousands of years. Yet, due to their legal status, there has been limited scientific research into the therapeutic potential of these compounds for psychiatric disorders. In the absence of other effective treatments however, researchers have begun again to systematically investigate such compounds and there is now evidence pointing to the use of psychedelic drugs in the treatment of addiction. In this review we focus on human evidence for the effectiveness of preparations used by indigenous cultures in the Amazon (ayahausca) and Africa (ibogaine) and worldwide (psilocybin), and more recently synthetised drugs such as the serotonergic hallucinogen LSD and the dissociative anaesthetic ketamine. Potential mechanisms explored are anti-depressant effects, changes in neuroplasticity and existential psychological effects of these drugs. ''If, therefore, under LSD we can have a temporary reduction, so that we can better see what we are and where we are going -well, that might be of some help. The goal might become clearer. So I consider LSD to be of some value to some people, and practically no damage to anyone.'' Bill Wilson, founder of Alcoholics Anonymous [Francis Hartigan, Bill W., Chapter 25, pp. 190-197 and pp. 170-171, St. Martins Press, 2000] .
The founder of alcoholics anonymous, Bill Wilson, is reported to have been treated with lysergic acid diethylamide (LSD) to help him stay abstinent from alcohol [1] and he credited it with helpful therapeutic properties. Yet the idea that illicit drugs can be used in the treatment of drug and alcohol addiction sits uncomfortably with many clinicians and researchers. It can appear paradoxical: illicit drugs are allegedly controlled due to their high abuse potential so it seems unethical to give them to people who already have a propensity for problematic alcohol and other drug use. Will they not then become addicted to the very substances that are being used to treat them? Centuries of practise and decades of research suggest that this is not the case. And now with emerging neurobiological understanding of their mechanisms, these compounds are poised to change the future of addiction treatment.
Lysergic acid diethylamide
LSD was first synthesised in 1938 from ergotamine, a chemical from the ergot fungus. LSD's psychological effects, usually last between 6 and 12 hours and can vary greatly in content across sets and settings [2] . Pharmacologically, LSD is a classic serotonergic hallucinogen, with its psychedelic effects attributed to its 5HT-2A receptor agonism [3] .
In the 1950s and 1960s, there was substantial research into LSD being used as a treatment for alcohol dependence [4] . In recent years, this interest has been reignited. A number of review papers and one meta-analysis have reviewed studies from the height of LSD research [5,6 ,7] . The meta-analysis [6 ] combined the results of 6 randomised controlled trials, to assess efficacy of LSD as a treatment for alcoholism (536 participants in total). Across the studies included, 59% of active treatment participants versus 38% of controls showed reliable improvement during the first follow up (1-2 months) and these differences were still reliable at 6 months. Whilst most research has focused on alcohol, one study of patients addicted to opioids treated with LSD demonstrated some degree of effectiveness [8] . Importantly, the first study on the acute effects of LSD on brain mechanisms in healthy volunteers was recently published [9] , which may herald a new era of medical use of the drug.
Psilocybin
Psilocybin is a compound that occurs naturally in over 200 species of mushrooms. Psilocybin mushrooms have been used as spiritual catalysts in indigenous cultures for millennia, where the mushrooms are revered as powerful spiritual sacraments that provide access to ancestors and other worlds. The effects of psilocybin last between 2 and 
